{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:11:14Z","timestamp":1791871874426,"version":"4.3.4"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Head and Neck Pathol"],"DOI":"10.1007\/s12105-026-01955-7","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:54:21Z","timestamp":1785887661000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Utility of Molecular Testing in Ameloblastoma: A Systematic Review with Functional Meta-synthesis and Exploratory Meta-analysis"],"prefix":"10.1007","volume":"20","author":[{"given":"Carlos M.","family":"Ardila","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Pineda-V\u00e9lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro I.","family":"D\u00edaz-Laclaustra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"issue":"10","key":"1955_CR1","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1111\/odi.15376","volume":"31","author":"X Zheng","year":"2025","unstructured":"Zheng X, Xia R, Zhu W, Qu C, Gu T, Robinson L et al (2025) Classic desmoplastic ameloblastoma: should it be a distinct subtype of ameloblastoma? Based on clinicopathological, radiological, immunohistochemical and molecular study of a large cohort. Oral Dis 31(10):2914\u20132925. https:\/\/doi.org\/10.1111\/odi.15376","journal-title":"Oral Dis"},{"issue":"7","key":"1955_CR2","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1111\/odi.15286","volume":"31","author":"Z You","year":"2025","unstructured":"You Z, Sima Z, Guo X, Li X, Feng Y, Du N et al (2025) Mutational landscape of ameloblastoma: analysis of BRAF and other key mutations in Chinese patients. Oral Dis 31(7):2215\u20132220. https:\/\/doi.org\/10.1111\/odi.15286","journal-title":"Oral Dis"},{"issue":"3","key":"1955_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2024.100682","volume":"38","author":"C Mar\u00edn-M\u00e1rquez","year":"2025","unstructured":"Mar\u00edn-M\u00e1rquez C, Adisa AO, Niklander SE, Kirby J, Hunter KD (2025) Genomic and transcriptomic analysis of ameloblastoma reveals distinct molecularly aggressive phenotypes. Mod Pathol 38(3):100682. https:\/\/doi.org\/10.1016\/j.modpat.2024.100682","journal-title":"Mod Pathol"},{"key":"1955_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12903-026-08325-3","author":"KA Hoang","year":"2026","unstructured":"Hoang KA, Nguyen CTK, Ho CQ, Duong TB, Luu TTT, Bui TTT et al (2026) BRAF and RAS mutations in Vietnamese patients with ameloblastoma. BMC Oral Health. https:\/\/doi.org\/10.1186\/s12903-026-08325-3","journal-title":"BMC Oral Health"},{"issue":"1","key":"1955_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jormas.2025.102575","volume":"127","author":"L Jayamani","year":"2026","unstructured":"Jayamani L, Bottu K, Joseph LD, Sekhar G (2026) Prevalence and clinicopathological correlation of BRAF V600E mutations in ameloblastoma: a PCR study from a tertiary centre in South India. J Stomatol Oral Maxillofac Surg 127(1):102575. https:\/\/doi.org\/10.1016\/j.jormas.2025.102575","journal-title":"J Stomatol Oral Maxillofac Surg"},{"key":"1955_CR6","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.19137","volume":"13","author":"KM Tun","year":"2025","unstructured":"Tun KM, Lapthanasupkul P, Iamaroon A, Thosaporn W, Klanrit P, Kintarak S et al (2025) A multi-center cross-sectional investigation of BRAF V600E mutation in ameloblastoma. PeerJ 13:e19137. https:\/\/doi.org\/10.7717\/peerj.19137","journal-title":"PeerJ"},{"issue":"3","key":"1955_CR7","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.oooo.2025.03.006","volume":"140","author":"M Huang","year":"2025","unstructured":"Huang M, Bradley G, Perez-Ordonez B, Klieb H, Blanas N, Magalhaes MAO (2025) Plexiform ameloblastoma: a potential diagnostic challenge. Oral Surg Oral Med Oral Pathol Oral Radiol 140(3):312\u2013321. https:\/\/doi.org\/10.1016\/j.oooo.2025.03.006","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"5","key":"1955_CR8","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1097\/PAS.0000000000002375","volume":"49","author":"IJ Stojanov","year":"2025","unstructured":"Stojanov IJ, Trzcinska AM, Qaisi M, Kmeid M, Azzato EM, Shah AA (2025) Novel histologic features in ameloblastoma with RASQ61R mutation. Am J Surg Pathol 49(5):508\u2013514. https:\/\/doi.org\/10.1097\/PAS.0000000000002375","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"1955_CR9","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1016\/j.jcms.2025.08.010","volume":"53","author":"S Crimi","year":"2025","unstructured":"Crimi S, Battaglia S, Giudice R, Ronsivalle V, Cicci\u00f9 M, Bianchi A (2025) Ameloblastoma: the association of BRAF V600E expression with clinicopathological characteristics and treatment outcomes in a case series. J Craniomaxillofac Surg 53(10):1911\u20131915. https:\/\/doi.org\/10.1016\/j.jcms.2025.08.010","journal-title":"J Craniomaxillofac Surg"},{"issue":"3","key":"1955_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jormas.2025.102700","volume":"127","author":"Y Li","year":"2026","unstructured":"Li Y, Liu K, Lu Y, Gan M (2026) VEGF mRNA expression as a powerful independent predictor for recurrence in ameloblastoma: integrating molecular profiling with surgical outcome analysis. J Stomatol Oral Maxillofac Surg 127(3):102700. https:\/\/doi.org\/10.1016\/j.jormas.2025.102700","journal-title":"J Stomatol Oral Maxillofac Surg"},{"issue":"3","key":"1955_CR11","doi-asserted-by":"publisher","first-page":"168","DOI":"10.5146\/tjpath.2022.01573","volume":"38","author":"M Soluk-Tekkesin","year":"2022","unstructured":"Soluk-Tekkesin M, Wright JM (2022) The World Health Organization classification of odontogenic lesions: a summary of the changes of the 2022 (5th) edition. Turk Patoloji Derg 38(3):168\u2013184. https:\/\/doi.org\/10.5146\/tjpath.2022.01573","journal-title":"Turk Patoloji Derg"},{"issue":"6","key":"1955_CR12","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1111\/odi.14962","volume":"30","author":"R Bologna-Molina","year":"2024","unstructured":"Bologna-Molina R, Schuch L, Magliocca K, van Heerden W, Robinson L, Bilodeau EA et al (2024) Targeted therapies in ameloblastomas and ameloblastic carcinoma-a systematic review. Oral Dis 30(6):3571\u20133581. https:\/\/doi.org\/10.1111\/odi.14962","journal-title":"Oral Dis"},{"issue":"4","key":"1955_CR13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.7181\/acfs.2025.0018","volume":"26","author":"LD Sulistyani","year":"2025","unstructured":"Sulistyani LD, Julia V, Ariawan D, Latief MA, Utomo YA, Aboy et al (2025) Molecular-targeted therapy in ameloblastoma: a systematic review. Arch Craniofac Surg. 26(4):133\u2013140. https:\/\/doi.org\/10.7181\/acfs.2025.0018","journal-title":"Arch Craniofac Surg."},{"issue":"22","key":"1955_CR14","doi-asserted-by":"publisher","first-page":"5593","DOI":"10.3390\/cancers14225593","volume":"14","author":"MN Mamat Yusof","year":"2022","unstructured":"Mamat Yusof MN, Ch\u2019ng ES, Abdul Rahman NR (2022) BRAF V600E mutation in ameloblastoma: a systematic review and meta-analysis. Cancers (Basel) 14(22):5593. https:\/\/doi.org\/10.3390\/cancers14225593","journal-title":"Cancers (Basel)"},{"issue":"3","key":"1955_CR15","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/jop.13278","volume":"51","author":"AV Martins-de-Barros","year":"2022","unstructured":"Martins-de-Barros AV, Anjos RS, Silva CCG, Silva EDO, Ara\u00fajo FAC, Carvalho MV (2022) Diagnostic accuracy of immunohistochemistry compared with molecular tests for detection of BRAF V600E mutation in ameloblastomas: systematic review and meta-analysis. J Oral Pathol Med 51(3):223\u2013230. https:\/\/doi.org\/10.1111\/jop.13278","journal-title":"J Oral Pathol Med"},{"key":"1955_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2020) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"1955_CR17","doi-asserted-by":"publisher","unstructured":"Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2020) PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 372:n160. https:\/\/doi.org\/10.1136\/bmj.n160","DOI":"10.1136\/bmj.n160"},{"issue":"1","key":"1955_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-020-01542-z","volume":"10","author":"ML Rethlefsen","year":"2021","unstructured":"Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ et al (2021) PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews. Syst Rev 10(1):39. https:\/\/doi.org\/10.1186\/s13643-020-01542-z","journal-title":"Syst Rev"},{"issue":"8","key":"1955_CR19","doi-asserted-by":"publisher","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","volume":"155","author":"PF Whiting","year":"2011","unstructured":"Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB et al (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155(8):529\u2013536. https:\/\/doi.org\/10.7326\/0003-4819-155-8-201110180-00009","journal-title":"Ann Intern Med"},{"issue":"3","key":"1955_CR20","doi-asserted-by":"publisher","first-page":"123","DOI":"10.15171\/ijhpm.2014.71","volume":"3","author":"Z Munn","year":"2014","unstructured":"Munn Z, Moola S, Riitano D, Lisy K (2014) The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence. Int J Health Policy Manag 3(3):123\u2013128. https:\/\/doi.org\/10.15171\/ijhpm.2014.71","journal-title":"Int J Health Policy Manag"},{"key":"1955_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ"},{"issue":"1","key":"1955_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.7326\/M18-1376","volume":"170","author":"KGM Moons","year":"2019","unstructured":"Moons KGM, Wolff RF, Riley RD, Whiting PF, Westwood M, Collins GS et al (2019) PROBAST: a tool to assess risk of bias and applicability of prediction model studies. Ann Intern Med 170(1):51\u201358. https:\/\/doi.org\/10.7326\/M18-1376","journal-title":"Ann Intern Med"},{"issue":"7650","key":"1955_CR23","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650):924\u2013926. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD","journal-title":"BMJ"},{"key":"1955_CR24","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jclinepi.2019.12.020","volume":"122","author":"HJ Schunemann","year":"2020","unstructured":"Schunemann HJ, Mustafa RA, Brozek J, Steingart KR, Leeflang M, Murad MH et al (2020) GRADE guidelines: 21 part 1. Study design, risk of bias, and indirectness in rating the certainty across a body of evidence for test accuracy. J Clin Epidemiol 122:129\u2013141. https:\/\/doi.org\/10.1016\/j.jclinepi.2019.12.020","journal-title":"J Clin Epidemiol"},{"key":"1955_CR25","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jclinepi.2019.12.021","volume":"122","author":"HJ Schunemann","year":"2020","unstructured":"Schunemann HJ, Mustafa RA, Brozek J, Steingart KR, Leeflang M, Murad MH et al (2020) GRADE guidelines: 21 part 2. Test accuracy: inconsistency, imprecision, publication bias, and other domains for rating the certainty of evidence and presenting it in evidence profiles and summary of findings tables. J Clin Epidemiol 122:142\u2013152. https:\/\/doi.org\/10.1016\/j.jclinepi.2019.12.021","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"1955_CR26","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177\u2013188. https:\/\/doi.org\/10.1016\/0197-2456(86)90046-2","journal-title":"Control Clin Trials"},{"issue":"7414","key":"1955_CR27","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557\u2013560. https:\/\/doi.org\/10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"issue":"11","key":"1955_CR28","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1136\/jech-2013-203104","volume":"67","author":"JJ Barendregt","year":"2013","unstructured":"Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T (2013) Meta-analysis of prevalence. J Epidemiol Community Health 67(11):974\u2013978. https:\/\/doi.org\/10.1136\/jech-2013-203104","journal-title":"J Epidemiol Community Health"},{"issue":"10","key":"1955_CR29","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.jclinepi.2005.02.022","volume":"58","author":"JB Reitsma","year":"2005","unstructured":"Reitsma JB, Glas AS, Rutjes AWS, Scholten RJPM, Bossuyt PM, Zwinderman AH (2005) Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 58(10):982\u2013990. https:\/\/doi.org\/10.1016\/j.jclinepi.2005.02.022","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"1955_CR30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/jop.13506","volume":"53","author":"A Anbinselvam","year":"2024","unstructured":"Anbinselvam A, Akinshipo AWO, Adisa AO, Effiom OA, Zhu X, Adebiyi KE et al (2024) Comparison of diagnostic methods for detection of BRAFV600E mutation in ameloblastoma. J Oral Pathol Med 53(1):79\u201387. https:\/\/doi.org\/10.1111\/jop.13506","journal-title":"J Oral Pathol Med"},{"issue":"2","key":"1955_CR31","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ijom.2023.06.001","volume":"53","author":"YD Ji","year":"2024","unstructured":"Ji YD, Johnson DN, Faquin WC, Peacock ZS (2024) Utility of BRAF V600E immunohistochemistry in the diagnosis of mandibular ameloblastomas. Int J Oral Maxillofac Surg 53(2):122\u2013126. https:\/\/doi.org\/10.1016\/j.ijom.2023.06.001","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"4","key":"1955_CR32","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/jnci\/djad232","volume":"116","author":"S Grynberg","year":"2024","unstructured":"Grynberg S, Vered M, Shapira-Frommer R, Asher N, Ben-Betzalel G, Stoff R et al (2024) Neoadjuvant BRAF-targeted therapy for ameloblastoma of the mandible: an organ preservation approach. J Natl Cancer Inst 116(4):539\u2013546. https:\/\/doi.org\/10.1093\/jnci\/djad232","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"1955_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s12105-024-01734-2","volume":"18","author":"A Hirschhorn","year":"2024","unstructured":"Hirschhorn A, Grynberg S, Campino GA, Dobriyan A, Patel V, Greenberg G et al (2024) Histopathologic and molecular insights following the management of ameloblastomas via targeted therapies - pathological and clinical perspectives. Head Neck Pathol 18(1):129. https:\/\/doi.org\/10.1007\/s12105-024-01734-2","journal-title":"Head Neck Pathol"},{"issue":"1","key":"1955_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s12105-024-01621-w","volume":"18","author":"AV Martins-de-Barros","year":"2024","unstructured":"Martins-de-Barros AV, da Costa Ara\u00fajo FA, Faro TF, de Aquino AAT, Barbosa Neto AG, da Silva HAM et al (2024) BRAF p.V600E mutational status does not correlate with biological behavior in conventional ameloblastomas: a disease-free survival analysis. Head Neck Pathol 18(1):23. https:\/\/doi.org\/10.1007\/s12105-024-01621-w","journal-title":"Head Neck Pathol"},{"issue":"4","key":"1955_CR35","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/jop.13529","volume":"53","author":"AV Martins-de-Barros","year":"2024","unstructured":"Martins-de-Barros AV, da Costa Ara\u00fajo FA, Barros AMI, Lazo R, Barbosa Neto AG, Ara\u00fajo F et al (2024) It was not possible to detect BRAF V600E mutation in circulating cell-free DNA from patients with ameloblastoma: a diagnostic accuracy study. J Oral Pathol Med 53(4):258\u2013265. https:\/\/doi.org\/10.1111\/jop.13529","journal-title":"J Oral Pathol Med"},{"issue":"4","key":"1955_CR36","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1002\/hed.27294","volume":"45","author":"JC Gates","year":"2023","unstructured":"Gates JC, Clark AP, Cherkas E, Shreenivas AV, Kraus D, Danzinger N et al (2023) Genomic profiling and precision medicine in complex ameloblastoma. Head Neck 45(4):816\u2013826. https:\/\/doi.org\/10.1002\/hed.27294","journal-title":"Head Neck"},{"issue":"4","key":"1955_CR37","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/jop.13399","volume":"52","author":"JYF Chang","year":"2023","unstructured":"Chang JYF, Lu PH, Tseng CH, Wang YP, Lee JJ, Chiang CP (2023) Factors affecting the accuracy of anti-BRAF V600E immunohistochemistry results in ameloblastomas. J Oral Pathol Med 52(4):342\u2013350. https:\/\/doi.org\/10.1111\/jop.13399","journal-title":"J Oral Pathol Med"},{"issue":"1","key":"1955_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41368-022-00170-8","volume":"14","author":"L Togni","year":"2022","unstructured":"Togni L, Zizzi A, Mazzucchelli R, Santarelli A, Rubini C, Mascitti M (2022) Identification of BRAF V600E mutation in odontogenic tumors by high-performance MALDI-TOF analysis. Int J Oral Sci 14(1):22. https:\/\/doi.org\/10.1038\/s41368-022-00170-8","journal-title":"Int J Oral Sci"},{"issue":"11","key":"1955_CR39","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/s41379-022-01105-8","volume":"35","author":"LD Mendez","year":"2022","unstructured":"Mendez LD, Wolsefer NS, Asa SL, Wasman J, Yoest JM, Stojanov IJ (2022) The diagnostic utility of BRAF VE1 mutation-specific immunohistochemistry in ameloblastoma. Mod Pathol 35(11):1570\u20131577. https:\/\/doi.org\/10.1038\/s41379-022-01105-8","journal-title":"Mod Pathol"},{"issue":"4","key":"1955_CR40","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1177\/10668969211064203","volume":"30","author":"K Kokubun","year":"2022","unstructured":"Kokubun K, Yamamoto K, Akashi Y, Chujo T, Nakajima K, Matsuzaka K (2022) Genetic study of BRAF V600E and SMO L412F mutations in Japanese patients with ameloblastoma. Int J Surg Pathol 30(4):378\u2013384. https:\/\/doi.org\/10.1177\/10668969211064203","journal-title":"Int J Surg Pathol"},{"issue":"8","key":"1955_CR41","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.ijom.2021.12.011","volume":"51","author":"S Kunmongkolwut","year":"2022","unstructured":"Kunmongkolwut S, Chaisuparat R (2022) Analysis of BRAF V600E expression and disease-free survival in patients with ameloblastoma. Int J Oral Maxillofac Surg 51(8):1034\u20131042. https:\/\/doi.org\/10.1016\/j.ijom.2021.12.011","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"8","key":"1955_CR42","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1136\/jclinpath-2021-207527","volume":"75","author":"R Bonacina","year":"2022","unstructured":"Bonacina R, Indini A, Massazza G, Rulli E, Gianatti A, Mandal\u00e0 M (2022) Correlation of BRAF mutational status with clinical characteristics and survival outcomes of patients with ameloblastoma: the experience of 11 Italian centres. J Clin Pathol 75(8):555\u2013559. https:\/\/doi.org\/10.1136\/jclinpath-2021-207527","journal-title":"J Clin Pathol"},{"issue":"5","key":"1955_CR43","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1097\/PAI.0000000000000904","volume":"29","author":"BMR da Silva Marcelino","year":"2021","unstructured":"da Silva Marcelino BMR et al (2021) Comparison of immunohistochemistry and DNA sequencing for BRAF V600E mutation detection in mandibular ameloblastomas. Appl Immunohistochem Mol Morphol 29(5):390\u2013393. https:\/\/doi.org\/10.1097\/PAI.0000000000000904","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"5","key":"1955_CR44","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/jop.12851","volume":"48","author":"KY Oh","year":"2019","unstructured":"Oh KY, Cho SD, Yoon HJ, Lee JI, Ahn SH, Hong SD (2019) High prevalence of BRAF V600E mutations in Korean patients with ameloblastoma: clinicopathological significance and correlation with epithelial-mesenchymal transition. J Oral Pathol Med 48(5):413\u2013420. https:\/\/doi.org\/10.1111\/jop.12851","journal-title":"J Oral Pathol Med"},{"issue":"5","key":"1955_CR45","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s00428-018-2305-5","volume":"472","author":"SE G\u00fcltekin","year":"2018","unstructured":"G\u00fcltekin SE, Aziz R, Heydt C, Seng\u00fcven B, Z\u00f6ller J, Safi AF et al (2018) The landscape of genetic alterations in ameloblastomas relates to clinical features. Virchows Arch 472(5):807\u2013814. https:\/\/doi.org\/10.1007\/s00428-018-2305-5","journal-title":"Virchows Arch"},{"issue":"5","key":"1955_CR46","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/path.4317","volume":"232","author":"KJ Kurppa","year":"2014","unstructured":"Kurppa KJ, Cat\u00f3n J, Morgan PR, Ristim\u00e4ki A, Ruhin B, Kellokoski J, Elenius K et al (2014) High frequency of BRAF V600E mutations in ameloblastoma. J Pathol 232(5):492\u2013498. https:\/\/doi.org\/10.1002\/path.4317","journal-title":"J Pathol"},{"issue":"7","key":"1955_CR47","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/ng.2986","volume":"46","author":"RT Sweeney","year":"2014","unstructured":"Sweeney RT, McClary AC, Myers BR, Biscocho J, Neahring L, Kwei KA et al (2014) Identification of recurrent SMO and BRAF mutations in ameloblastomas. Nat Genet 46(7):722\u2013725. https:\/\/doi.org\/10.1038\/ng.2986","journal-title":"Nat Genet"},{"issue":"21","key":"1955_CR48","doi-asserted-by":"publisher","first-page":"5517","DOI":"10.1158\/1078-0432.CCR-14-1069","volume":"20","author":"NA Brown","year":"2014","unstructured":"Brown NA, Rolland D, McHugh JB, Weigelin HC, Zhao L, Lim MS, Elenitoba-Johnson KS, Betz BL (2014) Activating FGFR2-RAS-BRAF mutations in ameloblastoma. Clin Cancer Res 20(21):5517\u20135526. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-1069","journal-title":"Clin Cancer Res"},{"issue":"17","key":"1955_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13175339","volume":"13","author":"R Gasparro","year":"2024","unstructured":"Gasparro R, Giordano F, Campana MD, Aliberti A, Landolfo E, Dolce P et al (2024) The effect of conservative vs. radical treatment of ameloblastoma on recurrence rate and quality of life: an umbrella review. J Clin Med 13(17):5339. https:\/\/doi.org\/10.3390\/jcm13175339","journal-title":"J Clin Med"},{"issue":"7","key":"1955_CR50","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1111\/odi.13014","volume":"25","author":"FN Hendra","year":"2019","unstructured":"Hendra FN, Natsir Kalla DS, Van Cann EM, de Vet HCW, Helder MN, Forouzanfar T (2019) Radical vs conservative treatment of intraosseous ameloblastoma: systematic review and meta-analysis. Oral Dis 25(7):1683\u20131696. https:\/\/doi.org\/10.1111\/odi.13014","journal-title":"Oral Dis"},{"issue":"Suppl 1","key":"1955_CR51","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00292-022-01152-7","volume":"43","author":"R Buettner","year":"2022","unstructured":"Buettner R, G\u00fcltekin SE (2022) Molecular diagnostics in odontogenic tumors. Pathologie (Heidelb) 43(Suppl 1):81\u201385. https:\/\/doi.org\/10.1007\/s00292-022-01152-7","journal-title":"Pathologie (Heidelb)"},{"issue":"1","key":"1955_CR52","doi-asserted-by":"publisher","first-page":"31","DOI":"10.5306\/wjco.v11.i1.31","volume":"11","author":"R Gonz\u00e1lez-Gonz\u00e1lez","year":"2020","unstructured":"Gonz\u00e1lez-Gonz\u00e1lez R, L\u00f3pez-Verd\u00edn S, Lavalle-Carrasco J, Molina-Frechero N, Isiordia-Espinoza M, Carre\u00f3n-Burciaga RG et al (2020) Current concepts in ameloblastoma-targeted therapies in B-raf proto-oncogene serine\/threonine kinase V600E mutation: systematic review. World J Clin Oncol 11(1):31\u201342. https:\/\/doi.org\/10.5306\/wjco.v11.i1.31","journal-title":"World J Clin Oncol"},{"issue":"3","key":"1955_CR53","doi-asserted-by":"publisher","first-page":"323","DOI":"10.4103\/ijdr.ijdr_456_22","volume":"33","author":"TR Yoithapprabhunath","year":"2022","unstructured":"Yoithapprabhunath TR, Srichinthu KK, Gupta D, Singh D, Pasupuleti S, Nirmal RM (2022) Effectiveness of molecular-targeted chemotherapy in ameloblastomas: a systematic review. Indian J Dent Res 33(3):323\u2013331. https:\/\/doi.org\/10.4103\/ijdr.ijdr_456_22","journal-title":"Indian J Dent Res"},{"issue":"4","key":"1955_CR54","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/cyt.13485","volume":"36","author":"P Pisapia","year":"2025","unstructured":"Pisapia P, Iaccarino A, Troncone G, Malapelle U (2025) Liquid biopsy in solid tumours: an overview. Cytopathology 36(4):296\u2013302. https:\/\/doi.org\/10.1111\/cyt.13485","journal-title":"Cytopathology"},{"issue":"2","key":"1955_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/medsci14020183","volume":"14","author":"CM Ardila","year":"2026","unstructured":"Ardila CM, Pineda-V\u00e9lez E, Vivares-Builes AM, D\u00edaz-Laclaustra AI (2026) Artificial-intelligence-based radiologic, histopathologic, and molecular models for the diagnosis and classification of malignant salivary gland tumors: a systematic review and functional meta-synthesis. Med Sci (Basel) 14(2):183. https:\/\/doi.org\/10.3390\/medsci14020183","journal-title":"Med Sci (Basel)"},{"issue":"3","key":"1955_CR56","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/odi.70121","volume":"32","author":"CM Ardila","year":"2026","unstructured":"Ardila CM, Vivares-Builes AM, Pineda-V\u00e9lez E (2026) Molecular biomarkers and machine learning in oral cancer: a systematic review and meta-analysis. Oral Dis 32(3):617\u2013637. https:\/\/doi.org\/10.1111\/odi.70121","journal-title":"Oral Dis"}],"container-title":["Head and Neck Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12105-026-01955-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12105-026-01955-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12105-026-01955-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:54:22Z","timestamp":1785887662000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12105-026-01955-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1955"],"URL":"https:\/\/doi.org\/10.1007\/s12105-026-01955-7","relation":{},"ISSN":["1936-0568"],"issn-type":[{"value":"1936-0568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"assertion":[{"value":"2 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to declare.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For this type of study ethics approval is not required.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For this type of study consent to participate is not required.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Consent for publication is not required.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"90"}}